National Survey on Infiltrative Breast Cancer (CSI)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00696527
First received: June 10, 2008
Last updated: December 9, 2010
Last verified: December 2010
  Purpose

The purpose of this observational study is to describe radiological, clinical and histological characteristics of women with infiltrative breast cancer.


Condition
Infiltrative Breast Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: National Prospective Survey on Women With a Diagnosis of Infiltrative Breast Cancer

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Radiological, Clinical and Histological characteristics [ Time Frame: Once ]

Secondary Outcome Measures:
  • Treatments: Surgery, radiotherapy, chemotherapy, hormonotherapy. [ Time Frame: Once ]

Estimated Enrollment: 1500
Study Start Date: June 2007
Study Completion Date: July 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

First ten consecutive women with infiltrative breast cancer seen by oncologists, and fulfilling eligibility criteria.

Criteria

Inclusion Criteria:

  • Women> or = 18 years old
  • Women with newly diagnosis of infiltrative breast cancer
  • Agree to take part in this study

Exclusion Criteria:

  • Women with other malignant tumor (except in situ cervical carcinoma or treated basal cell carcinoma)
  • Women with in situ ductal carcinoma or in situ lobular carcinoma
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00696527

  Show 136 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Alain Castaigne, Medical Director AstraZeneca
  More Information

No publications provided

Responsible Party: Alain Castaigne, Medical Director, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00696527     History of Changes
Other Study ID Numbers: NIS-OFR-DUM-2007/1
Study First Received: June 10, 2008
Last Updated: December 9, 2010
Health Authority: France: French Data Protection Authority

Keywords provided by AstraZeneca:
Infiltrative breast cancer-Clinical practice
Women with infiltrative breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on April 17, 2014